- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01570322
Determinants of Quality of Life Related to Health in Alzheimer Disease
June 8, 2016 updated by: CHU de Reims
Study the factors that explain Health-Related Quality of Life (HRQL) in patients with Alzheimer disease including:
- The influence of the environment (physical and human) on Health-Related Quality of Life (HRQL),
- The influence of non-drug and drug treatments on Health-Related Quality of Life (HRQL),
- The influence of formal and informal help mobilized,
- The influence of interactions "patient - caregiver" on Health-Related Quality of Life (HRQL),
- The influence of the ratio necessary cost on available resources on Health-Related Quality of Life (HRQL)
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
400
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jean-Luc NOVELLA, MD PhD
- Email: jlnovella@chu-reims.fr
Study Locations
-
-
-
Reims, France, 51092
- Recruiting
- CHU de Reims
-
Contact:
- Jean-Luc NOVELLA, MD PhD
- Email: jlnovella@chu-reims.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
75 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
- Patients with Alzheimer disease (DSM IV - Diagnostic and Statistical Manual of Mental Disorders - and NINCDS/ADRDA - National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association)
- Patients with MMSE (Mini Mental State Examination) > or = 10
Description
Inclusion Criteria:
- Patients with Alzheimer disease (DSM IV and NINCDS-ADRDA)
- Patients with MMSE (Mini Mental State Examination) > or = 10
- Out patients
Exclusion Criteria:
- Severe sensory disturbances,
- Non French speaking
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Health-Related Quality of Life (HRQOL) Assessment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
April 2, 2012
First Submitted That Met QC Criteria
April 2, 2012
First Posted (Estimate)
April 4, 2012
Study Record Updates
Last Update Posted (Estimate)
June 9, 2016
Last Update Submitted That Met QC Criteria
June 8, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PN09004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States